Systolic Time Intervals During Spironolactone Treatment of Digitalized and Non-digitalized Patients with Ischaemic Heart Disease

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1982 Jan 1

PMID 7056270

Citations 5

Authors

S Waldorff

J Berning

J Buch

E Steiness

Affiliations

Soon will be listed here.

Abstract

The effect of spironolactone on cardiac contractility indices was studied by externally recording systolic time intervals in four digitalized and four non-digitalized patients with ischaemic heart disease. A negative inotropic effect was found after spironolactone 100mg b.i.d. in all eight patients, as measured by an increase in pre-ejection period index PEPI (p less than 0.01), and the ratio between pre-ejection period and left ventricular ejection time PEP/LVET (p less than 0.001), while pre- and afterload remained constant. As expected, digoxin exerted a positive inotropic effect, as a decrease was observed in PEPI (p less than 0.01), and PEP/LVET (p less than 0.001). It was not possible to ascertain whether the observed effect was caused by a pharmacological interaction at receptor level between spironolactone and digoxin, or indirectly to changes in endogenous substances e.g. aldosterone. The results suggest that spironolactone may have unintended side effects in patients with severe heart failure and that its use be reevaluated.

Citing Articles

The acute effects of amiloride and potassium canrenoate on digoxin-induced positive inotropism in healthy volunteers.

Richter J, Sommers D, Snyman J, Millard S Eur J Clin Pharmacol. 1993; 45(2):195-6.

PMID: 8223845 DOI: 10.1007/BF00315506.

Cardiac glycosides. Drug interactions of clinical significance.

Magnani B, Malini P Drug Saf. 1995; 12(2):97-109.

PMID: 7766341 DOI: 10.2165/00002018-199512020-00003.

Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscle.

Mugge A, Schmitz W, Scholz H Klin Wochenschr. 1984; 62(15):717-23.

PMID: 6492693 DOI: 10.1007/BF01725704.

Pharmacokinetic interactions with digoxin.

Rodin S, Johnson B Clin Pharmacokinet. 1988; 15(4):227-44.

PMID: 3056649 DOI: 10.2165/00003088-198815040-00003.

Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics.

Cheitlin M, Byrd R, Benowitz N, Liu E, Modin G Cardiovasc Drugs Ther. 1991; 5(4):719-25.

PMID: 1888694 DOI: 10.1007/BF03029746.

References

Waldorff S, Andersen J, NIELSEN O, MOLTKE E, Sorensen U, Steiness E . Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther. 1978; 24(2):162-7. DOI: 10.1002/cpt1978242162. View

CSAPO G, Sohn Y, Yeh B . Electrophysiologic effects of potassium canrenoate on ouabain-induced ventricular dysrhythmias in rabbits. Pharmacology. 1974; 11(6):336-45. DOI: 10.1159/000136508. View

Sadee W, Dagcioglu M, Schroder R . Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973; 185(3):686-95. View

Steiness E . Renal tubular secretion of digoxin. Circulation. 1974; 50(1):103-7. DOI: 10.1161/01.cir.50.1.103. View

Musgrave G, Born C, Davidson C, Hamrick M . Interaction of spironolactone and digoxin in dogs. J Pharmacol Exp Ther. 1977; 202(3):696-701. View

Buch J, Egeblad H, Hansen P, Kjaergard H, Waldorff S, Steiness E . Correlation between changes in systolic time intervals and left ventricular end-diastolic diameter after preload reduction. Non-invasive monitoring of pharmacological intervention. Br Heart J. 1980; 44(6):668-71. PMC: 482463. DOI: 10.1136/hrt.44.6.668. View

Schroder R, Schuren K, Biamino G, Meyer V, Sadee W . [Positive-inotropic heart effect of aldadiene-potassium (Aldactone pro injections)]. Klin Wochenschr. 1971; 49(19):1093-6. DOI: 10.1007/BF01732923. View

Baskin S, Akera T, Puckett C, Brody S, BRODY T . Effect of potassium canrenoate on cardiac functions and (Na + + K + )-activated ATPase. Proc Soc Exp Biol Med. 1973; 143(2):495-8. DOI: 10.3181/00379727-143-37351. View

Kotter V, Leitner E, Arbeiter G, CORDES R, Schroder R . [Influence of canrenoate potassium (aldactone pro injections) on hemodynamics and myocardial ischemia in experimental myocardial infarct]. Z Kardiol. 1975; 64(7):672-86. View

10.

Waldorff S, Buch J . Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients. Eur J Cardiol. 1979; 10(2):143-9. View

11.

Jelliffe R, Brooker G . A nomogram for digoxin therapy. Am J Med. 1974; 57(1):63-8. DOI: 10.1016/0002-9343(74)90769-4. View

12.

Karim A, Zagarella J, Hribar J, Dooley M . Spironolactone. I. Disposition and metabolism. Clin Pharmacol Ther. 1976; 19(2):158-69. DOI: 10.1002/cpt1976192158. View

13.

BEVEGARD S, Castenfors J, Danielson M . The effects of four months' treatment with spironolactone on systemic blood pressure, cardiac output and plasma renin activity in hypertensive patients. Acta Med Scand. 1977; 202(5):373-7. DOI: 10.1111/j.0954-6820.1977.tb16846.x. View

14.

CORABOEUF E, Deroubaix E . Effect of a spirolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium. J Pharmacol Exp Ther. 1974; 191(1):128-38. View

15.

Ochs H, Greenblatt D, BODEM G, Smith T . Spironolactone. Am Heart J. 1978; 96(3):389-400. DOI: 10.1016/0002-8703(78)90052-2. View

16.

Strauer B . The influence of the aldosterone-antagonist spironolactone on myocardial contractility. Arch Int Pharmacodyn Ther. 1973; 201(1):59-70. View

17.

WEISSLER A, Harris W, SCHOENFELD C . Systolic time intervals in heart failure in man. Circulation. 1968; 37(2):149-59. DOI: 10.1161/01.cir.37.2.149. View

18.

Schroder R, Ramdohr B, HUTTEMANN U, Schuren K . [Direct positive inotropic cardiac effect of aldactone (spironolactone, canrenoate-K)]. Dtsch Med Wochenschr. 1972; 97(41):1535-8. DOI: 10.1055/s-0028-1107597. View

19.

Fricke U . Lack of interaction of spironolactone with ouabain guinea pig isolated heart muscle preparations. Eur J Pharmacol. 1978; 49(4):363-71. DOI: 10.1016/0014-2999(78)90310-2. View

20.

Yeh B, Sung P, LAZZARA R . The specificity of potassium canrenoate, a steroidal antidysrhythmic drug. Clin Pharmacol Ther. 1974; 16(6):1014-22. DOI: 10.1002/cpt19741661014. View